Nutraceuticals

This randomized, double-blind, placebo-controlled study investigated Ageratum conyzoides (A. conyzoides) for alleviating osteoarthritis symptoms and improving quality of life. Conducted in Australia between 2021 and 2024, the study included 70 adults aged ≥45 years with clinically diagnosed osteoarthritis. Participants consumed 250 mg of pyrrolizidine alkaloid-free A. conyzoides extract or a placebo daily for 12 weeks. Pain and function were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) every three weeks. Secondary measures included pain assessed by the Visual Analogue Scale (VAS), the SF-36 quality-of-life questionnaire, inflammatory markers, and safety parameters. A. conyzoides supplementation resulted in significant reductions in total WOMAC scores at weeks 9 and 12 (p < 0.05) compared to placebo. VAS pain scores were significantly lower at weeks 9 and 12 (p < 0.05). SF-36 scores improved significantly in the pain and role limitations due to physical health domains (p < 0.05). Plasma inflammatory markers IL-6 and IL-8 showed significant reductions compared with placebo (p < 0.05). No between-group differences were observed for adverse events. These findings demonstrate that A. conyzoides supplementation is a safe and effective option for reducing osteoarthritis symptoms, with significant improvements observed in pain, function, and inflammatory markers.

Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide and an endocannabinoid-related lipid that has been extensively studied for its analgesic, immunomodulatory, antimicrobial, and anti-inflammatory properties. It has demonstrated efficacy in various applications and is currently utilized as a nutraceutical for its antinociceptive, neuroprotective, and immunomodulatory effects, particularly in supporting brain and joint health and in mitigating inflammatory processes. Background/Objectives: Despite its significant therapeutic potential, the clinical effectiveness of PEA is limited by its poor water solubility and, consequently, low oral bioavailability. Additionally, degradation in the acidic gastrointestinal environment further compromises its absorption. To address these challenges, several technological strategies have been explored to improve its pharmacokinetic profile, including conventional micronization and ultra-micronization techniques. The objective of this study was to characterize a novel liposomal formulation based on PEA and evaluate its intestinal permeation and absorption. Methods: Comparative permeation studies of PEA were conducted using ex vivo models to evaluate its absorption characteristics across gastrointestinal mucosae. The experiments were performed in a Franz diffusion cell system using a porcine colon mucosa in two physiologically relevant media: Simulated Gastric Fluid (SGF) and Fasted State Simulated Intestinal Fluid (FaSSIF). Results: Liposomal PEA showed a more efficient and continuous release over time, reaching higher concentrations of PEA permeated through the membrane. Conclusions: Our findings demonstrate a significant improvement in PEA’s permeability and absorption in an ex vivo simulated gastrointestinal environment. Liposomal PEA appears to be more affine to biological membranes. These results suggest that liposomal PEA may represent a promising therapeutic strategy for managing chronic pain and inflammatory conditions such as chronic pelvic pain.

Bacteriocins from lactic acid bacteria have attracted considerable attention as natural alternatives to conventional antimicrobial agents. Weissellicin LM85, a bacteriocin purified from Weissella confusa LM85, has been less extensively studied in terms of its mechanism of action and potential applications. In this study, purified weissellicin LM85 exhibited potent inhibitory effects against Gram-positive bacteria, with minimum inhibitory and bactericidal concentrations determined against Micrococcus luteus MTCC106. Time-kill assays and fluorescence staining indicated a concentration-dependent reduction in cell viability, accompanied by membrane disruption. Further analyses revealed potassium ion efflux, dissipation of membrane potential (Δψ) and pH gradient (ΔpH), genomic DNA fragmentation, and pronounced morphological alterations in target cells. These findings are strongly suggestive of membrane-targeted bactericidal activity, likely involving pore-forming effects. In addition, weissellicin LM85 inhibited both growth and biofilm formation of Salmonella enterica subsp. enterica serovar Typhimurium ATCC13311 and Staphylococcus aureus subsp. aureus ATCC25923. Mechanistic analyses revealed the disruption of cell membrane integrity, leakage of potassium ions, cytoplasmic contents, and non-specific DNA degradation, indicating a multifaceted antibacterial mode of action. These findings highlight weissellicin LM85 as a promising natural antimicrobial with potential applications in food preservation and the control of foodborne pathogens and biofilm-associated infections. Further studies on cytotoxicity and in vivo efficacy are required to advance its practical application.